On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...
In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Barchart on MSN14d
Up 285% YTD, Is It Too Late to Buy This Biotech Stock?That includes San Diego-based Viking Therapeutics (VKTX), a pre-revenue clinical-stage biotech company that specializes in ...
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
智通财经获悉，生物技术公司Viking Therapeutics(VKTX.US)股价周一盘前截至发稿上涨23.90%，此前该公司公布了其实验性减肥药的令人鼓舞的结果，高剂量药物的减肥效果明显。与此同时，礼来和诺和诺德的股价盘前分别下跌2.6%和1%。 该公司周日在圣安东尼奥举行的ObesityWeek会议上发表报告称，在一项早期研究中，服用100毫克VK2735的患者在28天后平均减轻了8.2% ...
智通财经APP获悉，Viking Therapeutics (VKTX.US)周一早些时候公布的减肥药VK2735的数据表明，目前主导肥胖药物领域的诺和诺德 (NVO.US)和礼来 (LLY.US)未来可能面临严峻竞争。
Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported fourth quarter EPS of $-0.260, $0.03 worse than the analyst estimate of $-0.230. Revenue for the quarter came in at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback